letters & comments

NHC Comments on Medicare Drug Price Negotiation Program: Draft Guidance, Implementation of Sections 1191 – 1198 of the Social Security Act for Initial Price Applicability Year 2027 and Manufacturer Effectuation of the Maximum Fair Price (MFP) in 2026 and 2027

07/02/2024 Read More

NHC Comments on Medicare Advantage and Prescription Drug Programs: Part C and Part D Medicare Prescription Payment Plan Model Documents (CMS-10882) – IRA

06/27/2024 Read More

NHC Comments on Response to the Medicare Program; Request for Information on Medicare Advantage Data

05/29/2024 Read More

NHC Comments on Key Information and Facilitating Understanding in Informed Consent

04/30/2024 Read More

NHC Comments on Medicare Advantage and Prescription Drug Programs: Part C and Part D Medicare Prescription Payment Plan Model Documents

04/29/2024 Read More

NHC Statement for House Energy and Commerce Hearing

04/10/2024 Read More

NHC Statement on House Ways and Means Telehealth Hearing

03/25/2024 Read More

NHC Comments on Medicare Prescription Payment Plan

03/18/2024 Read More

NHC Response to the House Education and the Workforce RFI on ERISA Plans

03/15/2024 Read More
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19